共 17 条
[1]
Mortality by cause for eight regions of world:Global Burden of Disease Study. Murray CJ,Lopez AD. The Lancet . 1997
[2]
Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from90056participants in14randomised trials of statins. Cholesterol Treatment Trialists(CCT)Collaborators. The Lancet . 2005
[3]
Statin in stroke pre-vention and carotid atherosclerosis:systematic review and up-to-date meta-analysis. Amarenco P,Labreuche J,Lavalleie P,et al. Stroke . 2004
[4]
Interventions in the manage-ment of serum lipids for preventing stroke recurrence[Cochrane Review]. Manktelow B,Gillies C,Potter JF. Cochrane Database of Systematic Reviews . 2002
[5]
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in20,536high risk individuals:a randomized placebo-controlled trial. Heart Protection Study Collaborative Group. The Lancet . 2002
[6]
Differential effects of lipid-lowering therapies on stroke prevention:a meta-analysis of randomized trials. Corvol JC,Bouzamondo A,Sirol M,et al. Archives of Internal Medicine . 2003
[7]
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease(LIPID)Study Group. The New England Journal of Medicine . 1998
[8]
Reduction of stroke events with pravastatin:the PPP project. Byington RP,Davis BR,Plehn J F. Circulation . 2001
[9]
Prosper Study Group-prospective study of pravastatin in the elderly at risk:pravastatin in elderly individuals at risk of vascular disease(PROSPER):a randomized controlled trial. Shepherd J,Blauw GJ,Murphy MB,et al. The Lancet . 2002
[10]
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations. Sever PS,Dahlof B,Poulter NR,et al. The Lancet . 2003